Addiction
December 1, 2002
Jon C. Cole, Mike Bailey, Harry Sumnall et al.
149 citations
In 2001, ecstasy tablets seized in north-west England contained between 20 and 109 mg of MDMA, with most tablets averaging 60–69 mg. Some tablets also contained MDEA. The most common type, Mitsubishi tablets, spanned the full range of MDMA content. Analysis of 80 samples from a single large seizure of White Dove tablets showed low variation, indicating consistent manufacturing. Comparing these data with UK-wide analyses from 1991 to 2001 shows that the average MDMA content in ecstasy tablets has been declining over the decade. The authors argue that because the amount of MDMA per tablet is dropping, studies of long-term effects and neurotoxicity must account for actual ingested doses.
Journal of psychopharmacology (Oxford, England)
September 1, 2006
Harry Sumnall, Jon C. Cole, Lisa Jerome
117 citations
The subjective effects of MDMA (ecstasy) vary across different user groups and are shaped by the reasons people give for taking the drug. A 130-item survey was developed and analyzed, revealing six distinct categories of effects: perceptual alterations, entactogenic effects, prosocial effects, aesthetic effects, negative effects, and sexual effects. Heavier users expected fewer negative, perceptual, and aesthetic effects than lighter users, while abstainers expected greater negative, perceptual, aesthetic, and sexual effects. The findings suggest that extra-psychopharmacological factors, such as the function of use, influence the drug experience, and targeting intervention strategies to specific user groups based on their reasons for use may improve effectiveness.
BMJ
July 6, 2010
Simon D. Brandt, Harry Sumnall, Fiona Measham et al.
57 citations
After mephedrone was banned, internet vendors began selling substitute products. One widely promoted second-generation compound is Energy 1 (NRG-1), also called naphyrone (naphthylpyrovalerone, O-2482). This substance comes from a group of compounds originally documented in medicinal chemistry research.
Current Opinion in Psychology
April 1, 2021
Ian Hamilton, Harry Sumnall
Research on the link between cannabis use and psychotic symptoms has advanced over four decades but remains complex. While some insights into the nature of this relationship have been gained, major gaps persist in understanding the full trajectory of cannabis psychosis. Treatment options are limited, and there is little evidence to reliably predict who is at risk, which could enable early intervention to reduce incidence, though complete elimination is unrealistic.